Dravet Syndrome Market Size Worth $557.17 Million By 2032 | CAGR: 9.4%

The global dravet syndrome market size is expected to reach USD 557.17 million by 2032, according to a new study by Polaris Market Research. The report “Dravet Syndrome Market Share, Size, Trends, Industry Analysis Report, By Type of seizures (Myoclonic seizures, Atonic seizures, Partial seizures, Tonic-clonic seizures, photosensitive seizures Others); By Diagnosis; By Severity; By Treatment; By End-Use; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market's revenue growth will most likely be driven by enhanced genetic testing, which has increased the probability of Dravet syndrome diagnosis. An increase in improved regulatory environment for the healthcare sector and government funding for R&D has contributed to growth in the revenue of market. Improved healthcare infrastructure and greater healthcare budgets are expected to promote market revenue growth during the projected period. Increasing R&D initiatives for the discovery of innovative medications for syndrome are projected to drive growth in the future.

The U.S. FDA authorized the approval of the Diacomit in August 2020, for treating seizures linked with Dravet syndrome. Drug market share is expected to expand significantly after 2020 as a result of improved efficiency, safety, & longer seizure relief. Dravet syndrome is an exceedingly unusual neurological disorder that is typically lifelong. According to the Dravet Foundation, 1 in every 15,700 newborns born in the United States has Dravet syndrome.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/dravet-syndrome-market/request-for-sample

Encoded's precision gene therapy seeks to treat gait issues, ataxia (poor coordination), and developmental delays. It is intended to treat mutations in the SCN1A gene, which are the cause of the majority of Dravet cases, by increasing endogenous SCN1A expression in a particular cell type in the brain. The therapy increased SCN1A expression in a subset of inhibitory interneurons. Encoded intends to begin clinical trials for the therapy in early 2021. As numerous rich nations face a failure of these specifics, the increased demand for COVID-19 operation curatives has created enormous eventualities for manufacturers. Because of the need for vaccinations and treatment specifics for COVID-19, biopharma assiduity is likely to increase significantly in future. This, in turn, is projected to have a major influence on the dravet syndrome market as an effect of COVID-19.

Dravet Syndrome Market Report Highlights

• Myoclonic Seizures held the largest revenue share as it affects both sides of the brain simultaneously. It is widely used for children with Dravet syndrome and other epileptic conditions.
• The hospital pharmacies lead the market segment because of the availability and accessibility of innovative therapies and equipment.
• The global players include Biscayne, Cyberonics, INSYS Therapeutics, Epygenix Therapeutics, GW Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical, ThermoFisher Life, OPKO Health, Xenon Pharmaceutical, and Zogenix.

Polaris Market Research has segmented the Dravet syndrome market report based on form type of seizures, diagnosis, severity, treatment, end-use, distribution channel, and region:

Dravet Syndrome, Type of seizures Outlook (Revenue - USD Million, 2019 - 2032)

• Myoclonic Seizures
• Atonic Seizures
• Partial Seizures
• Tonic-Clonic Seizures
• Photosensitive seizures
• Others

Dravet Syndrome, Diagnosis Outlook (Revenue - USD Million, 2019 - 2032)

• MRI
• EEG
• SCN1A testing

Dravet Syndrome, Severity Outlook (Revenue - USD Million, 2019 - 2032)

• Mild
• Moderate
• Severe

Dravet Syndrome, Treatment Outlook (Revenue - USD Million, 2019 - 2032)

• Seizure Medication
• Clobazam
• Stiripentol
• Sodium Valproate
• Others
• Ketogenic Diet
• Vagus Nerve Stimulation

Dravet Syndrome, End-Use Outlook (Revenue - USD Million, 2019 - 2032)

• Pharmaceutical companies
• Hospitals
• Diagnostic Laboratories
• Academic and Research Institutions
• Others

Dravet Syndrome, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

• Direct tender
• Hospital pharmacy
• Retail Pharmacy
• Others

Dravet Syndrome, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa